Mark Alles has served on BioMarin’s Board of Directors since January 2022 and serves as Chair of the Corporate Governance and Nominating Committee. Mr. Alles is the chairman and Chief Executive Officer of TORL BioTherapeutics, LLC a position he has held since January 2024.

Previously, Mr. Alles served as Chairman and Chief Executive Officer of Celgene Corporation He held these roles from February 2018 until Celgene was acquired by Bristol Myers Squibb Company in November 2019. He was Celgene’s Chief Executive Officer from March 2016, spending a total of 15 years at Celgene in a number of senior roles and commercial management positions. Before joining Celgene, he held senior commercial management roles at Aventis Pharmaceuticals Inc. (Rhône-Poulenc Rorer) from 1993 to 2004.

Mr. Alles was Chairman of Turning Point Therapeutics, Inc., prior to its acquisition by Bristol Myers Squibb in August 2022. He currently serves on the boards of Antengene Corporation Limited and Syros Pharmaceuticals, Inc., both public biopharmaceutical companies.

Mr. Alles holds a B.S. in Health and Physical Education from Lock Haven University of Pennsylvania and served in the United States Marine Corps achieving the rank of Captain.